Skip to main content


16-03-2018 | Prostate cancer | Highlight | Article

Editor's pick

EBRT plus brachytherapy stands out for high-risk prostate cancer

External beam radiotherapy plus brachytherapy and radical prostatectomy are both suitable options for men with high-risk prostate cancer, while EBRT–BT appears to be the optimal regimen for Gleason score 9–10 disease, indicate the results of two studies.


J Clin Oncol 2018; Advance online publication, JAMA 2018; 319: 896–905

19-03-2018 | Prostate cancer | News | Article

Regulatory update

EMA issues warning for radium-223 dichloride in prostate cancer

The EMA has recommended against the concomitant use of radium-223 dichloride in men who are receiving abiraterone acetate plus prednisone/prednisolone for prostate cancer.

15-03-2018 | Head and neck cancer | News | Article

News in brief

High odds of opioid prescriptions for head and neck cancer

The likelihood of being prescribed opioids is greater for patients with head and neck cancer than for those with lung or colon cancer, findings indicate.

15-03-2018 | Prostate cancer | News | Article

Equal survival benefits shown with abiraterone vs docetaxel for prostate cancer

There is no survival difference between patients receiving abiraterone acetate plus prednisolone or docetaxel plus prednisolone for the long-term treatment of high-risk locally advanced or metastatic prostate cancer, STAMPEDE data show.


Ann Oncol 2018; Advance online publication

14-03-2018 | Breast cancer | News | Article

ACE inhibitors, beta blockers may protect against anthracycline-associated cardiotoxicity

The results of two independent trials suggest a role for the prophylactic use of angiotensin converting enzyme inhibitors or beta blockers in patients receiving an anthracycline-based regimen for HER2-positive or HER2-negative breast cancer.


ACC 2018; Orlando, Florida, USA, J Am Coll Cardiol 2018; Advance online publication

TACE Plus RT Might Be Best For HCC With Macroscopic Vessel Invasion

For patients with hepatocellular carcinoma with macroscopic vascular invasion, transarterial chemoembolization plus radiotherapy may be a better first-line option than sorafenib Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits